Treatment of Primary Cryofibrinogenemia in the Absence of Cryoglobulinaemia and Without Secondary Cause
This protocol applies to cryofibrinogenemia presenting without detectable cryoglobulinaemia, without an identifiable secondary cause, and without evidence of other vaso-occlusive disease — a primary, isolated presentation requiring a specific therapeutic approach.
Defining Clinical Criteria
- Absence of cryoglobulinaemia
- No secondary cause of cryofibrinogenaemia identified
- No evidence of other vaso-occlusive disease
Therapeutic Approach & Goals
In this setting, fibrinolytic therapy is among the approaches considered, particularly when patients present with severe ischaemic manifestations. The clinical target is improvement with disappearance of plasma cryofibrinogen.
The complete agent selection, administration schedule, and full management algorithm are available in the structured protocol →
References
DOI: 10.1093/rheumatology/kew379
- Absence of cryoglobulinaemia
- No secondary cause of cryofibrinogenaemia
- No evidence of other vaso-occlusive disease
- Fibrinolysis may be considered in the acute phase in patients with severe ischaemic manifestations of CF, though the need for i.v. administration limits its use for prolonged treatment.
- Daily i.v. administration of alteplase at a low dose (10 mg) led to dramatic clinical improvement and the disappearance of CF.
- Some authors suggest that routine use of intravenous streptokinase or other fibrinolytics is justified in patients with CF, though in fact experience with this kind of treatment is quite limited.
View source ↗